PF 5161704

Drug Profile

PF 5161704

Alternative Names: PF-05161704; PF5161704

Latest Information Update: 28 Mar 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
  • 13 Aug 2010 Phase-I clinical trials in Type-2 diabetes mellitus (in healthy volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top